Respiratory - chronic obstructive pulmonary disease
About LYNPARZA®
-
Marketed by AstraZeneca
-
Poly ADP ribose polymerase (PARP) inhibitor
-
Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, metastatic breast, metastatic pancreatic or primary peritoneal cancer who have had complete or partial response to platinum-based chemotherapy
